Literature DB >> 8215290

In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis.

S V Gollapudi1, S K Chuah, T Harvey, H D Thadepalli, H Thadepalli.   

Abstract

We investigated the in vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis. These quinolones did not alter the helper/suppressor ratio but did modulate the kinetics of tumor necrosis factor production in infected animals. This result correlated with the observed therapeutic efficacies of the quinolones.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8215290      PMCID： PMC188049          DOI： 10.1128/AAC.37.8.1711

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Aryl-fluoroquinolone derivatives A-56619 (difloxacin) and A-56620 inhibit mitogen-induced human mononuclear cell proliferation.

Authors:  S V Gollapudi; B Vayuvegula; S Gupta; M Fok; H Thadepalli
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

2.  A soluble suppressor T cell factor protects against experimental intraabdominal abscesses.

Authors:  D F Zaleznik; R W Finberg; M E Shapiro; A B Onderdonk; D L Kasper
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

3.  Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.

Authors:  B P Imbimbo; G Broccali; M Cesana; F Crema; G Attardo-Parrinello
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

4.  Interleukin-1 production by antibiotic-treated human monocytes.

Authors:  Y Roche; M Fay; M A Gougerot-Pocidalo
Journal:  J Antimicrob Chemother       Date:  1988-05       Impact factor: 5.790

5.  A novel mitogen released by lipid A-stimulated bone marrow cells.

Authors:  S V Gollapudi; M Kern
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

6.  Enhancement of interleukin 2 production by quinolone-treated human mononuclear leukocytes.

Authors:  Y Roche; M Fay; M A Gougerot-Pocidalo
Journal:  Int J Immunopharmacol       Date:  1988

7.  Evaluation of temafloxacin in a rat model of intra-abdominal abscess.

Authors:  H Thadepalli; M Hajji; V K Perumal; S K Chuah; S Gollapudi
Journal:  J Antimicrob Chemother       Date:  1992-06       Impact factor: 5.790

8.  Cellular control of abscess formation: role of T cells in the regulation of abscesses formed in response to Bacteroides fragilis.

Authors:  M E Shapiro; D L Kasper; D F Zaleznik; S Spriggs; A B Onderdonk; R W Finberg
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

9.  4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro.

Authors:  A Forsgren; S F Schlossman; T F Tedder
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

10.  Cellular immunity to Bacteroides fragilis capsular polysaccharide.

Authors:  M E Shapiro; A B Onderdonk; D L Kasper; R W Finberg
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307
View more
  6 in total

1.  Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors.

Authors:  Jibran Ahmed; Arun Kumar; Kaushal Parikh; Asad Anwar; Bettina M Knoll; Carmelo Puccio; Hoo Chun; Michael Fanucchi; Seah H Lim
Journal:  Oncoimmunology       Date:  2018-08-20       Impact factor: 8.110

2.  In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.

Authors:  H Thadepalli; U Reddy; S K Chuah; F Thadepalli; C Malilay; R J Polzer; N Hanna; A Esfandiari; P Brown; S Gollapudi
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

3.  In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Authors:  P M Furneri; G Bisignano; G Cerniglia; G Nicoletti; M Cesana; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

4.  Biliary excretion of rufloxacin in humans.

Authors:  G Privitera; G Nicastro; B P Imbimbo; M Cesana; M Visconti; F Lombardi; G Tagliabue; E Faleschini; F Colturani; P Franzini
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

5.  Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines.

Authors:  Taly Weiss; Itamar Shalit; Hannah Blau; Sara Werber; Drora Halperin; Avital Levitov; Ina Fabian
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 6.  Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.

Authors:  Temilolu Idowu; Frank Schweizer
Journal:  Antibiotics (Basel)       Date:  2017-11-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.